Yujia Liu, Lixiang Wang, Yiyi Li, Cheng Zhong, Xiumei Wang, Xinyu Wang, Zijin Xia, Jing Liao, Chunliu Huang, Chengzhou Mao, Yongyi Feng, Congzhou Luo, Wenhao Mai, Hongrui Song, Hongyu Li, Lin Bao, Danchun Chen, Yue Sheng, Hui Zhang, Xiaolei Wei, Jun Chen, Wei Yi
PURPOSE: Leukaemia remains a major contributor to global mortality, representing a significant health risk for a substantial number of cancer patients. Despite notable advancements in the field, existing treatments frequently exhibit limited efficacy or recurrence. Here, we explored the potential of abolishing HVEM (herpes virus entry mediator, TNFRSF14) expression in tumours as an effective approach to treat acute lymphoblastic leukaemia (ALL) and prevent its recurrence. METHODS: The clinical correlations between HVEM and leukaemia were revealed by public data analysis...
May 29, 2024: Cellular Oncology (Dordrecht)